Inhibitors of specific RBPs, such as LIN28, IGF2BPs, HuR, and Musashi, have shown efficacy in decreasing tumor growth, enhancing the differentiation of cancer cells, and reducing resistance to chemotherapy. Here, ELAVL1 is linked to cancer.